

1 **PREDICTION OF ALL-CAUSE MORTALITY AND CARDIOVASCULAR EVENTS IN END STAGE**
2 **RENAL DISEASE WITH CENTRAL HAEMODYNAMICS: A SYSTEMATIC REVIEW PROTOCOL**

3 Bárbara Letícia da Silva Guedes de Moura^{1,2}; Felipe Steinmacher Batista³; Guilherme Luiz Rodrigues
4 Ramajo³; Gustavo Bueno Valente³; João Vitor Scalon Estércio Rizzo³; Tarik Radi Campos Maftoum³; Izabel
5 Galhardo Demarchi⁴; Sérgio Seiji Yamada^{2,5}; Rogério Toshiro Passos Okawa^{2,3,5}; Jorge Juarez Vieira Teixeira
6 ^{2,6}.

7 blguedes@gmail.com; felipe1810@gmail.com; guilhermeramajo@gmail.com; gbvalente99@gmail.com;
8 joaovitorscalon13@gmail.com; tarikmaf@gmail.com; i.g.demarchi@ufsc.br; sergioyamada62@gmail.com;
9 rogerokawa@uol.com.br; ijvteixeira@gmail.com

10
11 **Authors' information:**

12 1 Graduate Program in Biosciences and Physiopathology (PBF), State University of Maringá,
13 Maringá, PR

14 2 Systemic Arterial Hypertension, Arterial Stiffness and Vascular Aging Research Group
15 (GPHARV/UEM)

16 3 Systemic Arterial Hypertension Academic League, Regional University Hospital, State
17 University of Maringá, PR, BR.

18 4 Clinical Analysis Department, Federal University of Santa Catarina (UFSC), SC

19 5 Medical Department, State University of Maringá, Maringá, PR

20 6 Clinical Analysis and Biomedicine Department, State University of Maringá, PR

21
22 **Institutional addresses:**

23 ^{1, 2, 3, 5, 6} State University of Maringá: Universidade Estadual de Maringá, Maringá – PR/BR. Av.
24 Colombo, 5790, Jd Universitário. CEP: 87.020-900\CCS. + 55 44 3011 4890.

25 ⁴Federal University of Santa Catarina (UFSC): Universidade Federal de Santa Catarina - CCS -
26 Departamento de Análises Clínicas Campus Universitário – Trindade. CEP: 88.040-970 -
27 Florianópolis – SC. Fone: +55 48 3721 4159.

28 **Corresponding author:**

29 **Barbara Leticia da Silva Guedes de Moura**

30 Av. Colombo, 5790 - Zona 7, Maringá - PR, 87020-900. Bloco I-90. sala 8. Prof. Jorge Teixeira.

31 www.uem.br

32 5544999281401

33 blsguedes@gmail.com

34

35 **ABSTRACT**

36

37 **Background:** Given the high rates of adverse events in End-stage renal disease (ESRD) patients
38 and as the applications of central haemodynamics (central blood pressure, augmentation index,
39 pulse wave velocity) in dialysis patients have not been fully clarified, we, therefore, will perform
40 a systematic review of central haemodynamics as a predictor of total and cardiovascular
41 mortality and morbidity in the ESRD population. **Methods:** This protocol is reported according
42 to the PRISMA-P guideline. The databases PubMed, EMBASE, LILACS, Web of Science, and
43 Google Scholar system will be searched and double screening for prospective studies that
44 assessed the prospective association of central haemodynamics parameters with at least one of
45 the pre-specified outcomes in ESRD patients. Discrepancies will be resolved through consensus.
46 A modified version of the Newcastle-Ottawa Quality Assessment Scale of cohort studies will be
47 used. We intend to use the random-effects model, considering at least moderate heterogeneity
48 between studies. If data allow, we will perform a sensitivity analysis to explore potential sources
49 of between-study heterogeneity. **Discussion:** This systematic review will summarize current
50 evidence about central haemodynamics measures in the ESRD patients and clarify the
51 incremental prognostic value of this diagnostic tool in these patients. Therefore, this systematic
52 review will also be displayed important knowledge gaps in the current literature regarding the
53 possible utility of central haemodynamics indices in ESRD patients.

54 **Systematic review registration**

55 This systematic review protocol was submitted to the PROSPERO international registry of
56 systematic reviews (Registration number: CRD42022260824).

57 **Keywords**

58 End-Stage renal disease; prognosis; central blood pressure; augmentation index; pulse wave
59 velocity.

60 **Strengths and limitations of this study**

61 → *The PROSPERO registry helps to promote and maintain transparency in the process and to*
62 *assist in minimizing the risk of bias. Four databases and one additional grey literature source*
63 *helps ensure more complete coverage of the topic. All the review phases will be peer-reviewed*
64 *and will be validated by methodological and clinical experts.*

65 → *Central (aortic, carotid) pressures are pathophysiologically more relevant than peripheral*
66 *pressures for the pathogenesis of cardiovascular (CV) disease. There is a cumulative increase in*
67 *CVD during the transition from CKD to ESRD: as patients initiate dialysis, there are significant*
68 *changes in blood pressure, volume status, and circulating solutes, all of which may contribute to*
69 *increased risk of CVD. Studies did not further analyze the ability of central pressures and indices*
70 *to predict future events in separated stages of CKD, especially in End-stage renal disease patients*
71 *(ESRD) patients.*

72 → *This study has limitations. Because heterogeneity is quite common in these systematic reviews,*
73 *there may be limited scope for meta-analysis. Possibly, the spectrum of patients in different*
74 *research sites is the main factor, in most cases, but heterogeneity in associations between studies*
75 *may be difficult to explain.*

76 → *This systematic review will evaluate the evidence related to the Central Haemodynamics*
77 *(central blood pressure, augmentation index, pulse wave velocity) incremental prognostic value*
78 *in ESRD patients, which may lower morbidity and mortality and influence its use as a prognostic*
79 *marker for ESRD patients.*

80 **Background**

81 End-stage renal disease (ESRD) is a rapidly increasing global health and health care burden. The
82 number of people receiving renal replacement therapy (RRT) exceeds 2.5 million and is
83 projected to double to 5.4 million by 2030 (1). Data from the US Renal Data System (USRDS)
84 reported that among CKD patients who die, 91% have a diagnosis of cardiovascular disease (CVD)
85 overall, 57% have a diagnosis of coronary (CAD), and 63% have a diagnosis of Heart Failure (HF).

86 Although classical Framingham risk factors remain important, there is increasing evidence to
87 support renal-specific and dialytic disturbances increases the CV risk in this population, such as
88 sodium/fluid balance, hyperuricemia, inflammation, vascular calcification, and abnormal bone
89 mineral metabolism, and these complex interaction results in a high prevalence of abnormalities
90 of cardiac structure and function in patients with ESRD (2,3).

91 Central (aortic, carotid) pressures are pathophysiologically more relevant than peripheral
92 pressures for the pathogenesis of cardiovascular (CV) disease. Central haemodynamics
93 (central/aortic blood pressure, augmentation index, pulse wave velocity) can now be reliably
94 assessed non-invasively with a number of relatively inexpensive devices (4). While several
95 studies have shown the ability of central pressures and indices to predict future events, findings
96 have not always been consistent in the ESRD patients (5). Studies did not further analyze central
97 haemodynamics in different stages of CKD, especially in ESRD patients. There is a cumulative
98 increase in CVD during the transition from CKD to ESRD: as patients initiate dialysis, there are
99 significant changes in blood pressure, volume status, and circulating solutes, all of which may
100 contribute to increased risk of CVD (3,6,7).

101 Given the high rates of adverse events in dialysis patients and as the applications of central
102 haemodynamics in dialysis patients have not been fully clarified, we, therefore, will perform a
103 systematic review of central haemodynamics as a predictor of total and cardiovascular mortality
104 and morbidity in the ESRD population.

105 **Methods/Design**

106 This protocol is reported according to the Preferred Reporting Items for Systematic
107 Reviews and Meta-Analyses Protocols (PRISMA-P) (8) and the corresponding checklist used
108 (Supplementary file 1). This includes details of inclusion and exclusion criteria, a data extraction
109 tool, and analytical methods. This systematic review protocol was submitted to the PROSPERO
110 international registry of systematic reviews (Registration number: CRD42022260824).

111 Review question

112 Is the Central Haemodynamics (central blood pressure, augmentation index, pulse wave
113 velocity) a better prognostic marker than peripheral measures (brachial blood pressure/
114 no control) in the End Stage Renal Disease?

115 P: End-stage renal disease patients

116 E: Central Haemodynamics (Central blood pressure, Augmentation Index and/or Pulse Wave
117 Velocity)

118 C: Peripheral (brachial) blood pressure / no restriction

119 O: All-cause mortality, cardiovascular events

120 S: Prospective studies

121 Searches

122 MEDLINE (using the PubMed interface), Web of Science, LILACS (Latin American and Caribbean
123 Literature in Health Sciences) and Google Scholar (grey literature) databases and reference lists
124 of eligible studies will be searched for publications until the search date. The Search strategy
125 were determined independently by three authors (BLSG, RTPO and JJVT). The search will be
126 limited to original research reports in peer-reviewed journals with no language or publication
127 date restriction.

128 Search strategy

129 The search strategy will be developed first for the MEDLINE database and the effectiveness will
130 be tested and refined accordingly, using the keywords 'Central Aortic Blood Pressure, 'Pulse
131 Wave Analysis', 'Vascular stiffness', 'chronic kidney disease', 'hemodialysis'. A detailed draft for
132 the search strategy to be used is detailed in Supplementary file 2.

133 Eligibility criteria

134 All longitudinal studies that assessed the prospective association of one or more index of central
135 haemodynamics (central blood pressure - cBP, Augmentation Index - Aix, or Pulse Wave Velocity
136 - PWV) with: (a) at least one of the pre-specified outcomes in ESRD (>18 years) population and
137 (b) in accordance with ethical standards, will be included and (c) Patients data with CKD in
138 different stages, (not only ESRD or which one that not reported the results separately according
139 to the CKD stage) and (d) Abstracts, reviews, conference proceedings or letters to the editor will
140 be excluded.

141 Search results from each database will be combined and duplicates will be removed before the
142 screening. References will be aggregated into a reference manager tool (EndNote Web) (9).
143 Additional papers will be identified by searching the reference lists of relevant articles and their
144 citation metrics.

145 A draft for the Eligibility and Data Extraction Form to be used is detailed in Supplementary file
146 3.

147 Outcomes and Measures of effect

148 The primary outcome will be all-cause mortality whereas secondary outcomes will be a
149 composite cardiovascular (endpoint includes: CV mortality, Coronary Heart Disease (CHD)
150 events (Myocardial infarction (MI), unstable angina, angina/ischemia requiring emergent
151 hospitalization or revascularization), Heart Failure (HF) hospitalization, new onset Atrial
152 Fibrillation (AF), life threatening arrhythmia, recorded automatic implantable cardioverter
153 defibrillator (AICD) shocks, stroke, transit ischemic attack, peripheral arterial disease (PAD) with
154 arterial revascularization procedure). Tertiary outcomes will be any individual secondary
155 endpoint not included in the composite cardiovascular.

156 We will provide a narrative synthesis of the findings from the included studies. We will provide
157 summaries of intervention effects for each study by calculating risk ratios (for dichotomous
158 outcomes) or standardized mean differences (for continuous outcomes) from the data
159 presented in the published studies or obtained from study authors.

160 Study reviews and appraisals

161 Initial title and abstract screening will be performed using Rayyan software (10) and full texts of
162 selected articles will be retrieved and double screened for eligibility and data extraction by six
163 researchers working independently (BLSGM, FSB, GLRR, GBV, JVSER, TRCM). Discrepancies will
164 be resolved through consensus or the opinion of a third review author (JJVT or RTPO) will be
165 sought. For multiple study publications from the same patient cohort, we will choose the study
166 with the largest number of cases, or which one that reported the results separately according
167 to the CKD stage, once there are many studies whose results of patients with early-to-moderate
168 CKD stage are reported together with ESRD patients, which makes it impossible to correctly
169 analyze these subgroups. For studies that presented different outcomes, we will be extracted
170 outcomes from both publications.

171 Reasons for study exclusion will be documented. Data extraction will be validated by
172 methodological and clinical experts (IGD, JJVT and RTPO, SSY, respectively). Also, information
173 reported in the grey literature will be sought. We will report our search terms as an appendix to
174 published studies.

175 Data extraction

176 We will extract the following data: (a) citation details (title, type, and year of publication); (b)
177 study details (name, region, and design of the study, sample size); (c) participant details
178 including demographics (age, sex, ethnicity, and follow-up duration), clinical (hypertension,
179 diabetes mellitus-DM, dyslipidemia, smoking status, and known CVD), and laboratory variables;
180 (d) exposure details (hardware and the software used for the measures acquisition and analysis);
181 (e) details of outcomes, including how these were ascertained; (f) statistical methods used, as
182 well as statistics related to the association of interest, and (g) information related to adjustment
183 for potential confounders.

184 If samples are reported at multiple time points within a study, then each one will be considered
185 individually. If these data are not available, we will extract the association measures that were
186 used. The relevant authors will not be contacted for further information.

187 Quality assessment, data synthesis, and exploration of heterogeneity

188 Risk of bias (quality) assessment

189 A modified version of the Newcastle-Ottawa Quality Assessment Scale of cohort studies (NOS)
190 (11) will be used to assess the quality of included papers (Supplementary file 4). Studies will not
191 be excluded from the main meta-analysis based on the risk of bias.

192 Strategy for data synthesis

193 Statistical analyses will be performed using Review Manager 5.4 software. This information will
194 be summarized graphically in the final review document. The degree of heterogeneity will be
195 assessed using the Higgins Thompson I^2 test (12) and Cochran's Q test (13). If the included
196 studies are sufficiently homogeneous, a quantitative synthesis using random-effect meta-
197 analysis will be used to pool the results of the association of interest. For presenting the results,
198 we will likely use the HR (95%CI) as an effect estimate and will present the data graphically in
199 forest plots. If data allow, we will perform a sensitivity analysis to explore potential sources of
200 between-study heterogeneity: (a) study quality, (b) variation in exposure measurement, and (c)
201 variation in CV outcomes definition. Possible publication bias will be assessed using a Funnel
202 plot (14). We will assess evidence of publication bias using Egger's weighted regression method
203 for continuous outcomes and Begg's rank correlation test for dichotomous outcomes.

204 Discussion

205 This systematic review will summarize current evidence about the incremental prognostic value
206 of central haemodynamics measures in the ESRD patients. Studies reported associations
207 between central haemodynamics measures and all-cause mortality and cardiovascular events,
208 but, is not fully understood the potential prognostic value of this diagnostic tool in ESRD
209 patients. Therefore, this systematic review will also be displayed important knowledge gaps in
210 the current literature regarding the possible utility of central haemodynamics indices in ESRD
211 patients.

212 Though hemodialysis (HD) should theoretically improve cardiovascular function by correcting
213 fluid overload and small molecule accumulation, cardiovascular mortality continues to be
214 disproportionately high in the HD population (1,2). The impact of renal replacement therapy
215 (RRT) on cardiovascular function and injury is not well understood and may inadvertently be
216 contributing to the accelerated development of type 4 cardiorenal syndrome (CRS): CKD leading
217 to an impairment of cardiac function. The unique physiology of cardiovascular abnormalities in
218 dialysis patients remains poorly understood and several more recently recognized factors,
219 including altered lipid metabolism and accumulation of gut microbiota-derived uremic toxins,
220 also affect cardiovascular function in the context of renal failure (15).

221 A crucial remaining question is whether central BP offers significant improvement in
222 cardiovascular risk assessment and stratification compared with brachial (peripheral) BP. Several
223 studies showed superiority of central compared with brachial BP; yet these findings have not
224 always been consistent.

225 This systematic review will provide essential data regarding central haemodynamics as
226 prognostic indicators of mortality and CV events in End-stage renal disease patients. The clinical
227 implications of this work relate to the current status of diagnosis and treatment of heart disease
228 in patients receiving dialysis.

229 Availability of data and materials

230 The datasets generated and/or analyzed during the current study are available from the
231 corresponding author on reasonable request.

232 List of Abbreviations

233 Aix: Augmentation Index

- 234 AF: Atrial fibrillation
- 235 AICD: Automatic implantable cardioverter defibrillator
- 236 BP: blood pressure
- 237 CHD: Coronary heart disease
- 238 CKD: chronic kidney disease
- 239 CRS: Cardiorenal syndrome
- 240 CV: Cardiovascular
- 241 CVD: Cardiovascular disease
- 242 DM: Diabetes mellitus
- 243 ESRD: End-stage renal disease
- 244 HD: Hemodialysis
- 245 HF: Heart failure
- 246 LILACS: Latin American and Caribbean Literature in Health Sciences
- 247 MI: Myocardial infarction
- 248 NOS: Newcastle-Ottawa Quality Assessment Scale of cohort studies
- 249 PRISMA-P: Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols
- 250 PROSPERO: International registry of systematic reviews
- 251 PP: Pulse pressure
- 252 PWV: Pulse wave velocity
- 253 RRT: Renal replacement therapy
- 254 UC: Uremic cardiomyopathy

255 **REFERENCES**

- 256 1. USRDS ADR. Epidemiology of kidney disease in the United States. National Institutes of
257 Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. 2019
258 november. Available from: <https://www.usrds.org/annual-data-report/>
- 259 2. Bansal N. Evolution of Cardiovascular Disease During the Transition to End-Stage Renal
260 Disease. *Semin Nephrol.* 2017 Mar;*37(2):120-131.* eng. doi:10.1016/j.semnephrol.2016.12.002.
261 Cited in: Pubmed; PMID 28410646.
- 262 3. Ibrahim MK, Kamal OMM, Hassan MS, Khalifa MMM. Interdialytic Weight Gain and Its
263 Relation to Outcome among Patients on Maintenance Hemodialysis. *QJM: An International*
264 *Journal of Medicine.* 2020 2020-03-01;*113(Supplement_1).* doi:10.1093/qjmed/hcaa052.020.
- 265 4. Battistoni A, Michielon A, Marino G, Savoia C. Vascular Aging and Central Aortic Blood
266 Pressure: From Pathophysiology to Treatment. *High Blood Press Cardiovasc Prev.* 2020
267 Aug;*27(4):299-308.* doi: 10.1007/s40292-020-00395-w. Epub 2020 Jun 22. PMID: 32572706.

- 268 5. Sabovic M, Safar ME, Blacher J. Is there any additional prognostic value of central blood
269 pressure wave forms beyond peripheral blood pressure? *Curr Pharm Des.* 2009;15(3):254-66.
270 doi: 10.2174/138161209787354249. PMID: 19149615.
- 271 6. Briet M, Boutouyrie P, Laurent S, London GM. Arterial stiffness and pulse pressure in CKD
272 and ESRD. *Kidney Int.* 2012 Aug;82(4):388-400. doi: 10.1038/ki.2012.131. PMID: 22534962.
- 273 7. Protogerou AD, Papaioannou TG, Lekakis JP, Blacher J, Safar ME. The effect of
274 antihypertensive drugs on central blood pressure beyond peripheral blood pressure. Part I:
275 (Patho)-physiology, rationale and perspective on pulse pressure amplification. *Curr Pharm Des.*
276 2009;15(3):267-71. doi: 10.2174/138161209787354267. PMID: 19149617.
- 277 8. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA.
278 Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P)
279 2015 statement. *Syst Rev.* 2015; 4(1):1. doi: 10.1186/2046-4053-4-1.
- 280 9. ENDNOTE WEB McKinney, A. EndNote Web: Web-Based Bibliographic Management. *Journal*
281 *of electronic resources in medical libraries*, 2013 10(4), 185-192.
- 282 10. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for
283 systematic reviews. *Systematic reviews*, 2016. 5(1), 210.
- 284 11. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. Newcastle-Ottawa
285 quality assessment scale cohort studies. 2014. 2015-11-19]. Available on: [http://www.](http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp)
286 [ohri.ca/programs/clinical_epidemiology/oxford. asp](http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp).
- 287 12. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ*
288 2003;327:557–60. 45. Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis.
289 *Stat Med* 2002;21:1539–58.
- 290 13. Cochran WG. The comparison of percentages in matched samples. *Biometrika*, 1950.
291 37(3/4), 256-266.
- 292 14. Sterne, JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, Tetzlaff J. Recommendations
293 for examining and interpreting funnel plot asymmetry in meta-analyses of randomised
294 controlled trials. *BMJ*, 2011 343.
- 295 15. Ahmadmehrabi S, Wilson Tang WH. Hemodialysis-induced cardiovascular disease. *Seminars*
296 *in Dialysis.* 2018; 31:258–267.

297 **DECLARATIONS**

298 Ethics approval and consent to participate: Not applicable.

299 Consent for publication: Not applicable.

300 Availability of data and materials: All data generated or analyzed during this study are included
301 in this published article [and its supplementary information files].

302 Competing interests: The authors declare that they have no competing interests.

303 Funding: None.

304 Authors' contributions: BLSGM has prepared this manuscript with clinical and methodological
305 support from RTPO and JJVT, respectively. This manuscript has been reviewed by FSB, GLRR,
306 GBV, JVSR, TRCM, IGD, SSY, RTPO and JJVT and edited by IGD, SSY, RTPO and JJVT. BLSGM is

307 the corresponding author and has registered the protocol with the PROSPERO database. All
308 authors agreed to be accountable for all aspects of this work and approved the final submission.

309 **Supplementary information**

Supplementary file 1: PRISMA-P Checklist.

Supplementary file 3: Eligibility Form / Data Extraction Form.

Supplementary file 2: Draft Search strategy.

Supplementary file 4: Modified NOS Risk of Bias assessment.

310